LC/MS/MS Analysis of Interacting Cardiac Drugs Digoxin, Quinidine, Amiodarone and Verapamil on Titan™ C18

LC/MS/MS Analysis of Interacting Cardiac Drugs Digoxin, Quinidine, Amiodarone and Verapamil on Titan™ C18

Conditions

sample/matrix Sample spiked into rat plasma
SPE well plate HybridSPE(R)-PLus 96-Well Plate (575659-U)
condition 100 uL of spiked rat plasma was added to the HybridSPE plate well, followed by 300 uL of protein precipitation solvent, acetonitrile with 1% formic acid. (The plate, sealed, secured on a vibrater, agitated by vibration at 1000 rpm for 2 min. The plate was transfered to a vacuum manifold. Vacuum was applied at 10 in Hg for 4 min.)
column Titan C18, 5 cm x 2.1 mm I.D., 1.9 µm particles (577122-U)
column temp. 35 °C
mobile phase [A] Water; [B] methanol, both with 0.1% formic acid/10 mM ammonium formate
gradient 0-1 min, 45%B; 1.5-4 min 90%B, 4.5-8 min 45%B 
flow rate 0.2 mL/min
pressure 2900 psi
injection 1 µL
detector MS, ESI(+), MRM mode

Description

Analysis Note Sample pretreatment: Sample spiked into rat plasma

Detector:
MRM transitions:
Peak MRM
1. Quinidine 325.2/81.1, 307.1
2. Verapamil 455.3/165.1
3. Digoxin 798.5/651.5
4. Amiodarone 646.1/58.1, 100.1
Categories Analytical Chromatography, Clinical, SPE Applications, cardiac drugs, Antihypertensives, antihypertensives, Cardiac Drugs, Cardiac drugs
Featured Industry Clinical
Legal Information HybridSPE is a registered trademark of Sigma-Aldrich Co. LLC, Titan is a trademark of Sigma-Aldrich Co. LLC
suitability application for LC-MS

Materials

     
Related Links